Position in PCVX
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$4,127
-$3,601 QoQ
Shares Held
71
-46.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#285
of 329 holders
Holding Since
Mar 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PCVX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MEEDER ASSET MANAGEMENT INC holds $6,351,882 across 34 Biotechnology names. PCVX ranks #23 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
7,156 | $4,462,048 | |
| 2 | CAI |
Caris Life Sciences, Inc.
|
34,035 | $606,501 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,570 | $472,613 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
|
5,009 | $186,384 | |
| 5 | MNPR |
Monopar Therapeutics
|
1,389 | $128,607 | |
| 6 | RAPP |
Rapport Therapeutics, Inc.
|
2,774 | $115,592 | |
| 7 | CRVS |
Corvus Pharmaceuticals, Inc.
|
6,055 | $90,461 | |
| 8 | ADMA |
Adma Biologics, Inc.
|
8,913 | $74,601 |
All Filings in PCVX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,127 | 71 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $7,728 | 133 | Shares | Sole | 2026-05-07 | |
| 2025-06-30 | $1,430 | 44 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $1,585 | 42 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $4,256 | 52 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $79,759 | 698 | Shares | Sole | 2024-11-07 | |
| 2024-06-30 | $4,757 | 63 | Shares | Sole | 2024-08-08 | |
| 2024-03-31 | $4,235 | 62 | Shares | Sole | 2024-05-07 | |
| No filing history on record for this holder in this stock. | ||||||